Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

NCT05999604 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

244

Enrollment

NETWORK

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab Injection [Ocrevus]
DRUG: Ocrelizumab Injection [Ocrevus]

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild